MRNA vs TECH

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

MRNA

35.2
AI Score
VS
TECH Wins

TECH

60.9
AI Score

Investment Advisor Scores

MRNA

35score
Recommendation
SELL

TECH

61score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA TECH Winner
Revenue 534.00M 893.85M TECH
Net Income -2.13B 127.24M TECH
Net Margin -397.9% 14.2% TECH
Operating Income -2.20B 177.61M TECH
ROE -31.4% 6.1% TECH
ROA -19.4% 5.0% TECH
Total Assets 10.96B 2.55B MRNA
Cash 1.72B 209.82M MRNA
Current Ratio 2.29 4.49 TECH
Free Cash Flow -1.25B 176.29M TECH

Relative Price Performance (Last 90 Days)

MRNA 1M: +11.3% · 3M: +274.8% TECH 1M: +0.1% · 3M: +1.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (56.8% over 20 days), RSI 51

RSI (14): 51.0 · Price: $202.63

TECH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 57.7 · Price: $72.62

Fundamentals Snapshot

Metric MRNA TECH
Market Cap — —
Forward P/E -42.4 42.7
Trailing P/E — 62.6
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin -0.7% 0.7%
Operating Margin -5.6% 0.3%
EPS -8.10 1.16
Dividend Yield — 0.00%

Frequently Asked Questions

Based on our detailed analysis, TECH is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.